Leading Indian drug maker Jubilant Life Sciences Tuesday announced it had received approval of the US Food and Drug Administration (FDA) for its tablets used in treating adults for various infections, including pneumonia.
"Levofloxacin tablets are the generic version of Levaquin of Ortho-McNeil, used for treating infections such as pneumonia, sinusitis, bronchitis, prostatitis, urinary tract and inhalational anthrax," the Noida-based firm said in a statement here.
According to IMS Health, the market size for Levofloxacin tablets is estimated to be $28 million (Rs.179 crore) per annum.
The company, which had 806 filings for formulations till March 31, got approval for 368 of them from various regions worldwide, including 72 from FDA.
As an integrated drug maker, Jubilant manufactures and supplies active pharmaceutical ingredients, solid dosage formulations, specialty pharmaceuticals and life science ingredients. The company also provides services in contract manufacturing and drug discovery solutions to global firms from its 10 production units in India, Canada and the US.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app